Pricefx Acquires AI Pricing Software Startup Brennus Analytics
7.5.2020 14:00:00 EEST | Business Wire | Press release
Pricefx, the global leader in native cloud pricing software, today announced it has acquired Brennus Analytics, an AI pricing software start-up based in France. Brennus uses a modular, proprietary AI technology to provide unique optimization capabilities highly applicable to the challenges of complex B2B environments. The transaction will bring state-of-art technology and a team of exceptionally talented AI and data science professionals to accelerate Pricefx’s AI capabilities in its price optimization software.
“In today’s fast-moving business climate, being able to use pricing as a lever to achieve revenue and profit goals is more important than ever,” said Marcin Cichon, CEO and co-founder at Pricefx. “The AI technology and deep bench of talent we are bringing in from Brennus will enable us to deliver strategic product enhancements that will allow Pricefx to set a new standard for price optimization. With Brennus, Pricefx is building on the impressive momentum we have already created in serving our customers with fast, flexible and friendly solutions for the past 9 years. Our goals and vision remain unchanged: using our Passion for Pricing to deliver the best pricing platform on the planet.”
Combining Brennus’ innovations in AI for pricing with Pricefx’s ability to productize and commercialize at scale brings to market a solution greater than the sum of its parts, enabling the company to better meet customers’ needs in a rapidly changing business climate. Additionally, Brennus’ location will enable Pricefx to expand its presence in France and better support existing customers in the region.
Brennus’ pricing optimization software is based on AI technology called “Adaptive Multi Agent Systems” (AMAS). AMAS technology is predictive, prescriptive, transparent, fast and flexible. Devised in the 1990s by the Toulouse Research Institute in Computer Science (IRIT), AMAS is based on self-organizing autonomous agent networks, comparable to a living organism. The self-adapting system is particularly well-suited for large scale optimization and continuous learning.
“Based on our unique AI technology, we have developed the most efficient price optimization solution on the market, but it can only reach its full potential when backed by a competitive pricing solution. By joining Pricefx, we’ve teamed up with the best one,” said Florent Dotto, CTO for Brennus Analytics. “Our technology is well suited to mass optimization, and unlike other AI technologies, such as machine learning, it is transparent, fast, requires no training time and can be reconfigured with new parameters on the go. Computation is executed almost in real time, allowing users to test any pricing optimization scenario on the fly.”
Brennus Analytics was founded in 2015 by Gregoire Saint-Guily, Florent Dotto, Sylvain Peyruqueou and Sylvain Rougemaille.
Financial terms of the deal were not disclosed. This is the first strategic acquisition that Pricefx has executed since closing its series B round of venture financing in November 2019.
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005039/en/
Contact information
Media Contact:
Cathy Summers
Summers PR
cathy@summers-pr.com
+1 (415) 483-0480
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tangent Robotics Raises 4.5M in Pre-seed Funding to Advance Fine Motor Skills for Robot Dexterity30.9.2026 17:23:00 EEST | Press release
In humans, fine motor skills can take two decades to fully develop. Tangent Robotics, which today announced its pre-seed funding round, aims to speed up the timeline for robots. The company will use the funds to develop skilled robotic manipulation capabilities at the intersection of hand hardware, touch sensing, and motor learning, and deploy them in demanding manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930237631/en/ Tangent Robotics is developing fine motor skills for robot hands, which unlock the ability to perform critical tasks for what we want our economy to build locally, fast and at scale "Fine motor skills are hard to learn, and represent a layer that is currently missing in robotics but omnipresent in the real world," says Pedro Piacenza, Tangent's co-founder. "They unlock the ability to perform delicate, intricate manipulation. Tasks like assembly, threading, connector mating, gas
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 16:00:00 EEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 16:00:00 EEST | Press release
Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization for protecting sensitive payment data. The result is a security-first approach in which payment protection is bui
Blackfuel Emerges From Stealth with More Than $250 Million in Contracted Revenue to Build a Global AI Token Grid30.9.2026 16:00:00 EEST | Press release
Blackfuel today emerged from stealth with more than $250 million in contracted revenue under multi-year customer agreements, unveiling its ambition to build a global AI Token Grid. Pioneering the AI Token Grid, Blackfuel is building a network of architecture-specific accelerator clusters connected through a common software and commercial layer, designed to turn dedicated compute into measurable, reservable AI output. By collaborating with AMD and NTT DATA, Blackfuel is developing its European-operated inference capacity, beginning with a GPU cluster currently being delivered in Europe. "The cloud was built around virtual machines. The next infrastructure layer will be built around tokens. We are building Blackfuel to become one of the world's defining AI compute companies, starting with our first deployments in Europe. That means bringing industrial-scale infrastructure, software and capital together so customers can buy intelligence with the same predictability with which they buy pow
Visioneering Technologies' New Contact Lens Trial Shows Landmark Results in Slowing Children's Nearsightedness30.9.2026 15:59:00 EEST | Press release
Visioneering Technologies, Inc. (VTI), a medical device company that designs and markets specialty contact lenses, will announce completed three-year results from PROTECT, a prospective, double-masked, multinational randomized controlled trial evaluating the company's NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens for slowing the progression of myopia, or nearsightedness, in children. Ashley Tuan, OD, MS, PhD, VTI's Chief Medical Officer, will present the full findings at the American Academy of Optometry's annual meeting in Anaheim. Myopia develops when a child's eye grows too long, causing distant objects to appear blurry, and it typically worsens through childhood. Faster progression is associated with a higher lifelong risk of more serious eye conditions, including retinal detachment and myopic maculopathy, a leading cause of permanent vision loss. Slowing that progression, even modestly, is considered clinically meaningful.3,4 Over three years, children who wore NaturalVu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom